ES2182327T3 - Derivados de (imidazol-5-il)metil-2-quinlinona como inhibidores de la proliferacion de celulas de musculos lisos. - Google Patents

Derivados de (imidazol-5-il)metil-2-quinlinona como inhibidores de la proliferacion de celulas de musculos lisos.

Info

Publication number
ES2182327T3
ES2182327T3 ES98928332T ES98928332T ES2182327T3 ES 2182327 T3 ES2182327 T3 ES 2182327T3 ES 98928332 T ES98928332 T ES 98928332T ES 98928332 T ES98928332 T ES 98928332T ES 2182327 T3 ES2182327 T3 ES 2182327T3
Authority
ES
Spain
Prior art keywords
sub
alkyl
sup
amino
alkyloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98928332T
Other languages
English (en)
Inventor
David William End
Michael J Zelesko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2182327T3 publication Critical patent/ES2182327T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere al empleo de compuestos de fórmula (I) en los que la línea de puntos representa un enlace opcional; X es oxigeno azufre; R{sup, 1} es H, alquilo C{sub, 1-12}, Ar{sup,1}, Ar{sup,2} alquilo -C{sub, 1-6}, quinolinil alquilo C{sub, 1-6}, piridinil C{sub, 1-6} alquilo, hidroxi alquilo C{sub, 1-6}, C{sub, 1-6} alcoxilo, alquilo C{sub, 1-6}, mono- o di(alquil C{sub, 1-6})amino alquilo C{sub, 1-6}, amino alquilo C{sub, 1-6}, o un radical de la fórmula -Alq {suo,1}-C(=O)-R{sup,9}, -Alq {sup,1}-S(O)-R{sup, 9}, o -Arq{sup,1}-S(O){sub,2}-R{sup, 9}; R{sup, 2}, R{sup, 3} y R{sup, 17}, cada uno independientemente son H, hidroxi, halo, ciano, alquilo C{sub, 1-6}, C{sub, 1-6} alcoxilo, hidorxi- alquiloxi C{sub, 1-6}, alquiloxi C{sub, 1-6}, amino alquiloxi C{sub, 1-6}, mono-o di(alquil C{sub, 1-6})amino alquiloxi C{sub, 1-6}, Ar{sup,1}, Ar{sup,2} alquilo C{sub, 1-6}, Ar{sup,2} oxi, Ar{sup,2}, alquiloxi C{sub, 1-6}, hidroxicarbonilo, alquiloxicarbonilo C{sub, 1-6}, trihalometilo, trihalometoxi, alquenilo C{sub, 2-6}, R{sup, 4} y R{sup, 5} cada uno independinetemente son H, Ar{sup,1}, alquilo C{sub, 1-6}, hidoroxi- alquilo C{sub, 1-6}, alquiloxi C{sub, 1-6}, alquilo C{sub, 1-6}, alquiloxi C{sub, 1-6}, alquiltio C{sub, 1-6}, amino, hidorcarbonilo, alquiloxicarbonilo C{sub, 1-6}, alquil C{sub, 1-6} S(O) alquilo C{sub, 1-6} o alquil C{sub, 1-6} S(O){sub,2} alquilo C{sub, 1-6}; R{sup,6} y R{sup,7} cada uno independientemente son H, halo, ciano, C{sub, 1-6} alquilo, 4,4-dimetil -oxazolilo, C{sub, 1-6}alquiloxilo o Ar{sup,2}oxy; R{sup,8} es H, C{sub, 1-6} alquilo, ciano, hidroxicarbonilo, C{sub, 1-6} alquiloxicarbonilo, C{sub, 1-6} alquilcarbonilo, C{sub, 1-6} alquilo, cianoC{sub, 1-6} alquilo, C{sub, 1-6} alquiloxicarbonil C{sub, 1-6} alquilo, alcoxi C{sub, 1-6} alquilo, hidroxi C{sub, 1-6} alquilo, amino C1-6 alquilo, mono-o di(C{sub, 1-6}alquil)amino C{sub, 1-6}alquilo, imidazolilo, halo, alquilo C{sub,1-6}, alcoxi C{sub,1-6} alquilo C{sub,1-6}, aminocarbonil alquilo C{sub,1-6} o u radical de fórmula -O-R{sup, 10}, -S-R{sup, 10}, -N-R{sup, 11}, O{sup, 12}; R{sup, 17} es H, halo, ciano, alquilo C{sub, 1-6}, alquiloxicarbonilo C{sub, 1-6}, Ar{sup,1}; R{sup, 18} es H, alquilo C{sub, 1-6}, alcoxilo o halo C{sub, 1-6}; R{sup, 19} es H o alquilo C{sub, 1-6} para la fabricación de un medicamento que inhibe la proliferación de células de músculo liso.
ES98928332T 1997-06-02 1998-05-25 Derivados de (imidazol-5-il)metil-2-quinlinona como inhibidores de la proliferacion de celulas de musculos lisos. Expired - Lifetime ES2182327T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4737697P 1997-06-02 1997-06-02

Publications (1)

Publication Number Publication Date
ES2182327T3 true ES2182327T3 (es) 2003-03-01

Family

ID=21948611

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98928332T Expired - Lifetime ES2182327T3 (es) 1997-06-02 1998-05-25 Derivados de (imidazol-5-il)metil-2-quinlinona como inhibidores de la proliferacion de celulas de musculos lisos.

Country Status (22)

Country Link
US (4) US6365600B1 (es)
EP (1) EP0988038B1 (es)
JP (1) JP4209472B2 (es)
KR (1) KR100517832B1 (es)
CN (2) CN1231215C (es)
AT (1) ATE222104T1 (es)
AU (1) AU740603B2 (es)
BR (1) BR9810423A (es)
CA (1) CA2290992C (es)
DE (1) DE69807222T2 (es)
DK (1) DK0988038T3 (es)
ES (1) ES2182327T3 (es)
HK (2) HK1025046A1 (es)
ID (1) ID24675A (es)
IL (1) IL133212A (es)
NO (1) NO318834B1 (es)
NZ (1) NZ501401A (es)
PT (1) PT988038E (es)
RU (1) RU2209066C2 (es)
TR (1) TR199902923T2 (es)
WO (1) WO1998055124A1 (es)
ZA (1) ZA984700B (es)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055124A1 (en) 1997-06-02 1998-12-10 Janssen Pharmaceutica N.V. (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation
US20030040790A1 (en) * 1998-04-15 2003-02-27 Furst Joseph G. Stent coating
US20020099438A1 (en) * 1998-04-15 2002-07-25 Furst Joseph G. Irradiated stent coating
ES2212580T3 (es) * 1998-07-06 2004-07-16 Janssen Pharmaceutica N.V. Inhibidores de la proteina farnesil-transferasa para el tratamiento de artropatias.
US7967855B2 (en) 1998-07-27 2011-06-28 Icon Interventional Systems, Inc. Coated medical device
US8070796B2 (en) 1998-07-27 2011-12-06 Icon Interventional Systems, Inc. Thrombosis inhibiting graft
EP1107962B1 (en) * 1998-08-27 2005-02-23 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
CN1178938C (zh) * 1998-12-23 2004-12-08 詹森药业有限公司 1,2-稠合的喹啉衍生物
DE60020812T2 (de) 1999-02-11 2006-05-04 Pfizer Products Inc., Groton Heteroaryl-substituierte chinolin-2-on derivate verwendbar als antikrebsmittel
DE60008206T2 (de) 1999-11-30 2004-12-02 Pfizer Products Inc., Groton Chinolinderivate verwendbar zur Hemmung der Farnesyl-Protein Transferase
US6844357B2 (en) * 2000-05-01 2005-01-18 Pfizer Inc. Substituted quinolin-2-one derivatives useful as antiproliferative agents
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
AU9327501A (en) 2000-09-11 2002-03-26 Chiron Corp Quinolinone derivatives
FR2813791B1 (fr) * 2000-09-14 2004-03-12 Lafon Labor Utilisation de 2- et 4-quinolones pour inhiber la neo-proliferation intimale
AU2001293829A1 (en) 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-((substituted phenyl)methyl)-quinoline and quinazoline derivatives
ES2313991T3 (es) 2000-09-25 2009-03-16 Janssen Pharmaceutica Nv Derivados de 6-heterociclilmetil-quinolina y quinazolina que inhiben la farnesil transferasa.
WO2002024687A1 (en) * 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
JP4911866B2 (ja) 2000-09-25 2012-04-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼ阻害剤としてのファルネシルトランスフェラーゼを阻害するキノリンおよびキナゾリン誘導体
DE60139080D1 (de) 2000-11-21 2009-08-06 Janssen Pharmaceutica Nv Farnesyltransferase hemmende benzoheterocyclische derivate
ATE319704T1 (de) 2000-12-27 2006-03-15 Janssen Pharmaceutica Nv Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
EP1408971A4 (en) 2001-06-21 2006-01-25 Ariad Pharma Inc NEW QUINOLINES AND THEIR USES
ES2323265T3 (es) 2001-12-19 2009-07-10 Janssen Pharmaceutica Nv Derivados de quinolina condensados en 1,8 sustituidos con triazoles unidos por el carbono como inhibidores de la farnesil-transferasa.
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
WO2003080058A1 (en) 2002-03-22 2003-10-02 Janssen Pharmaceutica. N.V. Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
US7511138B2 (en) 2002-04-15 2009-03-31 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
US8016881B2 (en) 2002-07-31 2011-09-13 Icon Interventional Systems, Inc. Sutures and surgical staples for anastamoses, wound closures, and surgical closures
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
US6638301B1 (en) * 2002-10-02 2003-10-28 Scimed Life Systems, Inc. Medical device with radiopacity
EP1565187A4 (en) 2002-11-13 2010-02-17 Novartis Vaccines & Diagnostic CANCER TREATMENT METHODS AND RELATED METHODS
US20050154451A1 (en) * 2003-12-18 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US7211108B2 (en) * 2004-01-23 2007-05-01 Icon Medical Corp. Vascular grafts with amphiphilic block copolymer coatings
KR101150172B1 (ko) * 2004-01-23 2012-05-25 얀센 파마슈티카 엔.브이. 치환된 퀴놀린 및 마이코박테리아 저해제로서의 용도
BRPI0507891A (pt) 2004-02-20 2007-07-24 Chiron Corp modulação dos processos inflamatório e metastático
RU2006136381A (ru) * 2004-03-15 2008-04-27 Анормед, Инк. (Ca) Способ получения антагониста cxcr4
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20050272068A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. UCH-L1 expression and cancer therapy
JP2007538004A (ja) * 2004-03-18 2007-12-27 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド シヌクレイノパチーを治療する方法
US20050277629A1 (en) * 2004-03-18 2005-12-15 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
JP2007529555A (ja) * 2004-03-18 2007-10-25 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド シヌクレイノパチーを治療する方法
US7063720B2 (en) * 2004-09-14 2006-06-20 The Wallace Enterprises, Inc. Covered stent with controlled therapeutic agent diffusion
US20060083770A1 (en) * 2004-10-15 2006-04-20 Specialty Coating Systems, Inc. Medical devices and methods of preparation and use
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
US9107899B2 (en) 2005-03-03 2015-08-18 Icon Medical Corporation Metal alloys for medical devices
US20060201601A1 (en) * 2005-03-03 2006-09-14 Icon Interventional Systems, Inc. Flexible markers
WO2006110197A2 (en) 2005-03-03 2006-10-19 Icon Medical Corp. Polymer biodegradable medical device
US7540995B2 (en) 2005-03-03 2009-06-02 Icon Medical Corp. Process for forming an improved metal alloy stent
US8323333B2 (en) * 2005-03-03 2012-12-04 Icon Medical Corp. Fragile structure protective coating
US20060264914A1 (en) * 2005-03-03 2006-11-23 Icon Medical Corp. Metal alloys for medical devices
US20060200048A1 (en) * 2005-03-03 2006-09-07 Icon Medical Corp. Removable sheath for device protection
CN102070614B (zh) 2005-05-23 2014-01-15 诺华股份有限公司 4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮乳酸盐的结晶和其它形式
NZ566180A (en) 2005-07-29 2011-04-29 Resverlogix Corp Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
EP2545919A1 (en) 2005-12-23 2013-01-16 Link Medicine Corporation Treatment of synucleinopathies
US20070148390A1 (en) * 2005-12-27 2007-06-28 Specialty Coating Systems, Inc. Fluorinated coatings
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
MX2009008099A (es) 2007-02-01 2009-12-14 Resverlogix Corp Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
EP2160386B1 (en) * 2007-05-23 2012-07-11 Allergan, Inc. Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds
WO2009151683A2 (en) * 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
NZ586440A (en) 2008-06-26 2011-07-29 Resverlogix Corp Methods of preparing quinazolinone derivatives
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
EP2370436A1 (en) * 2008-11-13 2011-10-05 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
EP2382194B1 (en) 2009-01-08 2014-03-12 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
WO2010106436A2 (en) 2009-03-18 2010-09-23 Resverlogix Corp. Novel anti-inflammatory agents
EP3431086B1 (en) 2009-04-22 2020-06-17 Resverlogix Corp. Novel anti-inflammatory agents
US8398916B2 (en) 2010-03-04 2013-03-19 Icon Medical Corp. Method for forming a tubular medical device
US9610251B2 (en) 2011-11-01 2017-04-04 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
EP2814814B1 (en) * 2012-02-13 2019-05-08 F.Hoffmann-La Roche Ag Imidazolylketone derivatives asd aldosterone synthase inhibitors
MX2015004784A (es) * 2012-10-16 2015-08-14 Janssen Pharmaceutica Nv Moduladores de quinolinilo unidos a fenilo de receptor nuclear de acido retinoico-gamma-t.
WO2014062655A1 (en) 2012-10-16 2014-04-24 Janssen Pharmaceutica Nv HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt
PL2909192T3 (pl) * 2012-10-16 2017-09-29 Janssen Pharmaceutica Nv Połączone metylenem modulatory chinolinylowe ROR-GAMMA-T
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
WO2014096965A2 (en) 2012-12-21 2014-06-26 Rvx Therapeutics Inc. Novel heterocyclic compounds as bromodomain inhibitors
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
WO2015057626A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv QUINOLINYL MODULATORS OF RORyT
AU2014334619A1 (en) 2013-10-15 2016-04-21 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORyt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
CN106535826A (zh) 2014-06-24 2017-03-22 怡康医疗股份有限公司 用于医疗装置的改进的金属合金
CA2972771C (en) * 2014-12-18 2024-06-11 University Of South Carolina Suppression of neointimal formation following vascular surgery using cdk8 inhibitors
CN114984016A (zh) 2015-03-13 2022-09-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
WO2016172342A1 (en) 2015-04-21 2016-10-27 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
SI3640345T1 (sl) 2015-08-17 2022-01-31 Kura Oncology, Inc. Postopki za zdravljenje rakavih pacientov z inhibitorji farneziltransferaze
CN109069426B (zh) 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
PL3393468T3 (pl) 2015-12-22 2023-01-23 X4 Pharmaceuticals, Inc. Metody leczenia niedoboru odporności
US11766506B2 (en) 2016-03-04 2023-09-26 Mirus Llc Stent device for spinal fusion
WO2017177230A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
CA3027495A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CN116554168A (zh) 2016-06-21 2023-08-08 X4 制药有限公司 Cxcr4抑制剂及其用途
CN109641838A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
EP3838275A1 (en) 2016-11-03 2021-06-23 Kura Oncology, Inc. Farnesyltransferase inhibitors for use in methods of treating cancer
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CN110204487B (zh) * 2019-06-21 2021-09-28 江南大学 一种喹啉衍生物的合成方法
CN113072490B (zh) * 2021-03-26 2022-08-16 中国海洋大学 一种替吡法尼喹啉酮中间体的高效合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE456347B (sv) 1982-02-09 1988-09-26 Ird Biomaterial Ab Ytmodifierat fast substrat samt forfarande for framstellning derav
US5049403A (en) 1989-10-12 1991-09-17 Horsk Hydro A.S. Process for the preparation of surface modified solid substrates
US5213898A (en) 1989-10-12 1993-05-25 Norsk Hydro A.S. Process for the preparation of surface modified solid substrates
US5356433A (en) 1991-08-13 1994-10-18 Cordis Corporation Biocompatible metal surfaces
JPH07112930A (ja) * 1993-10-14 1995-05-02 Kyowa Hakko Kogyo Co Ltd 血管平滑筋細胞増殖抑制剤
KR19990007865A (ko) 1995-04-19 1999-01-25 스피겔알렌제이 약물 방출용 피복 스텐트
US5607475A (en) 1995-08-22 1997-03-04 Medtronic, Inc. Biocompatible medical article and method
US5863904A (en) 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
EP1162201B1 (en) * 1995-12-08 2006-03-29 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
WO1998055124A1 (en) 1997-06-02 1998-12-10 Janssen Pharmaceutica N.V. (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation

Also Published As

Publication number Publication date
KR100517832B1 (ko) 2005-09-30
NZ501401A (en) 2002-03-28
ID24675A (id) 2000-07-27
CN1265585A (zh) 2000-09-06
CA2290992C (en) 2008-02-12
CN1762355A (zh) 2006-04-26
DE69807222T2 (de) 2003-04-17
ZA984700B (en) 1999-12-01
CN1231215C (zh) 2005-12-14
HK1025046A1 (en) 2000-11-03
RU2209066C2 (ru) 2003-07-27
JP4209472B2 (ja) 2009-01-14
WO1998055124A1 (en) 1998-12-10
NO995883L (no) 2000-02-02
JP2002503235A (ja) 2002-01-29
CN100525766C (zh) 2009-08-12
AU8020798A (en) 1998-12-21
DK0988038T3 (da) 2002-12-02
DE69807222D1 (de) 2002-09-19
US20020091138A1 (en) 2002-07-11
BR9810423A (pt) 2000-10-03
US6734194B2 (en) 2004-05-11
KR20010012782A (ko) 2001-02-26
IL133212A (en) 2005-12-18
US6365600B1 (en) 2002-04-02
US20030229118A1 (en) 2003-12-11
CA2290992A1 (en) 1998-12-10
TR199902923T2 (xx) 2000-11-21
US7253183B2 (en) 2007-08-07
US6743805B2 (en) 2004-06-01
IL133212A0 (en) 2001-03-19
NO318834B1 (no) 2005-05-09
EP0988038B1 (en) 2002-08-14
PT988038E (pt) 2002-12-31
AU740603B2 (en) 2001-11-08
NO995883D0 (no) 1999-12-01
US20040198771A1 (en) 2004-10-07
EP0988038A1 (en) 2000-03-29
ATE222104T1 (de) 2002-08-15
HK1088820A1 (en) 2006-11-17

Similar Documents

Publication Publication Date Title
ES2182327T3 (es) Derivados de (imidazol-5-il)metil-2-quinlinona como inhibidores de la proliferacion de celulas de musculos lisos.
ES2171736T3 (es) Derivados de 2-quinolona inhibidores de farnesil-transferasa.
UY27522A1 (es) Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
ES2189235T3 (es) 6-fenilfenantridinas sustituidas.
BG102458A (en) (imidazol-5-yl)methyl-2-quinoline derivatives inhibiting pharnesyl protein transferase
DE69810328T2 (de) Zusammenstellung aus gemischten cyanoacrylatestern
UY28674A1 (es) Inhibidores heterociclil amino de 11-beta-hidroxiesteroide deshidrogenasa tipo 1
YU3902A (sh) Imidazoimidazoli i triazoli kao anti-inflamatorna sredstva
ES2170605B1 (es) Nuevos fotoiniciadores de o-aciloximas.
ES2189207T3 (es) Inhibidores de hidroxamatos inversos de metaloproteinasas matriciales.
ATE276241T1 (de) Antioxidationsmittel
SV2002000244A (es) Metodos y compuestos para inhibir mrp1 ref.x-13353
PT979079E (pt) Utilizacao de derivados da tetra-hidropiridina para a preparacao de medicamentospara o tratamento das doencas que provocam uma desmielinizacao
AR117951A1 (es) Derivados de triazolquinoxalina adicionalmente sustituidos
ES2145971T3 (es) Procedimiento de preparacion de un cetal derivado de esteroide.
AR013360A1 (es) Derivados de 6-azauracilo inhibidores de il-5, procedimiento para su preparacion, composicion que los contiene, procedimiento para preparardicha composicion, uso de dicho compuesto para la manufactura de medicamentos, de composiciones y procedimiento de marcado de un receptor.
PE20011318A1 (es) Compuestos fenilo sustituidos inhibidores de la farnesiltransferasa
ATE415965T1 (de) Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung
ES2165407T3 (es) Compuestos beta-carbolina inhibidores de tromboxano sintasa.
ATE17727T1 (de) Alkylenverbrueckte guanidinothiazolderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel.
ES2148458T3 (es) Derivados de fenil-4-tiazoles sustituidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
EA200000412A1 (ru) Комбинация активных ингредиентов, в частности тетрагидропиридинов и агентов, ингибирующих ацетилхолинэстеразу, для лечения старческой деменции по типу альцгеймера
CO5210926A1 (es) Mezclas fungicidas
CO5050348A1 (es) Mezclas fungicidas que contienen fenil-bencil eteres y carboxamidas
CO5040009A1 (es) Mezclas fungicidas sinergicas que contienen un carbamato y n-acetoil benzamida